Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims

Blood (2022) 140 (Supplement 1): 6204–6205.

https://doi.org/10.1182/blood-2022-167468

Published: 2022

Journal Articles

Direct Intravital Imaging of the Bone Marrow and Splenic Hematopoietic Niches in Individual Mice to Define the Early Engraftment Kinetics Following HSC-Transplant

Augustine Vinson, Alexander Ligocki, Christopher R. Cogle, Edward Scott

Blood (2021) 138 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2021-151157

Published: 2021

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Justin M Watts, Tara L. Lin, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2021-149337

Published: 2021

Journal Articles

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Tara L. Lin, Justin M Watts, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2021-149366

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2021-151234

Published: 2021

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Gail J. Roboz, MD, Christopher R. Cogle, Daniel A. Pollyea, Mehrdad Abedi, MD, Michael A. Thompson, MD PhD, Melissa Nifenecker, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Michelle Little, Harry P. Erba

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-135877

Published: 2020

Journal Articles

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

David J. King, BS, Martina C. Murphy, MD, Rodney A. Schmidt, PhD, Matthew Lesser, MS, Alice Houk, MPS, Ellen Salkeld, PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 5418.

https://doi.org/10.1182/blood-2019-123474

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

Gregory Takacs, BS, Yujia Zhou, BS,BA, David J. King, BS, Amy Meacham, MS, Loguinov Alex, PhD, Abderrahmane Tagmount, PhD, Amin Sobh, PhD, Max Russo, BS, Chris D Vulpe, MD PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 1452.

https://doi.org/10.1182/blood-2019-128180

Published: 2019

Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD

Blood (2018) 132 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2018-99-114429

Published: 2018

Journal Articles

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Shireen Vali, PhD, Christopher R. Cogle, MD, Neeraj Arora, MD, Krishnan Shekhar, PhD, Mammen Chandy, MD, Manju Sengar, MD DM, Hasmukh Jain, MD DM, Girish Chinnaswamy, MD MRCP, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Anusha Pampana, M.Sc., Vijayashree P Shyamasundar, M.Sc., Huzaifa Sikora, B.Tech, Ansu Kumar, M.Sc., Taher Abbasi, MS, MBA, Vivek S Radhakrishnan, MDDM,MSc

Blood (2018) 132 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2018-99-116603

Published: 2018

Journal Articles

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Leylah M. Drusbosky, PhD, Robinson Vidva, B.Tech, Yugandhara Narvekar, M.Sc., Ashish Kumar Agrawal, B.V.Sc, A.H., Saji Gera, M.Tech, Samiksha Avinash Prasad, M.Sc., Vijayashree P Shyamasundar, M.Sc., Gaurav Singh Tunwer, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2018-99-115284

Published: 2018

Journal Articles

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Leylah M. Drusbosky, PhD, Diwyanshu Sahu, M.Sc., Robinson Vidva, B.Tech, Shweta Kapoor, M.Sc., Humera Azam, M.Sc., Rajeev Kumar, B.Tech, Padmagiri G Chickdipatti, B.E, Nithya T Raveendaran, M.Tech, Reshma P Gopi, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2018-99-115678

Published: 2018

Journal Articles

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Christopher R. Cogle, MD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Rahul K Raman, M.Sc., Robinson Vidva, B.Tech, Anuj Tyagi, M.Sc., Anay Ashok Talawdekar, M.Tech, Arko Das, M.Sc., Steven M. Kornblau, MD, Fieke W Hoff, BSc, Terzah M. Horton, MD PhD, Shireen Vali, PhD

Blood (2018) 132 (Supplement 1): 4034.

https://doi.org/10.1182/blood-2018-99-115775

Published: 2018

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Deepak Anil Lala, B.Tech, Poornachandra G, B.Tech, Saumya Radhakrishnan, B.Tech, Shivgonda C Birajdar, MCA, Ganesh Naga, B.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2018-99-115821

Published: 2018

NARROW

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Direct Intravital Imaging of the Bone Marrow and Splenic Hematopoietic Niches in Individual Mice to Define the Early Engraftment Kinetics Following HSC-Transplant

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only